Evidence map›Paper›PMID 39901537›Full record

SynthesisAnti-cancer agents in medicinal chemistry2025

A Systematic Review and Meta-analysis on the Safety and Efficacy of CAR T Cell Therapy Targeting GPRC5D in Patients with Multiple Myeloma: A New Insight in Cancer Immunotherapy.

Behrouz Robat-Jazi, Mehrdad Mahalleh, Mohsen Dashti, Negar Nejati, Mahsa Ahmadpour, Erfan Alinejad, Shiva Mohammadi, Parsa Lorestani, Amir Ali Hamidieh, Mohammad Amin Habibi and 1 more

Abstract readSystematic ReviewMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in Anti-cancer agents in medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Targets for CAR Therapy in Multiple Myeloma.International journal of molecular sciences · 2025
    Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Behrouz Robat-JaziInflammation Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Mehrdad MahallehRheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Mohsen DashtiImmunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Negar NejatiPediatric Cell and Gene Therapy Research Centre, Gene, Cell & Tissue Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
Mahsa AhmadpourShahid Faghihi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran.
Erfan AlinejadFaculty of Medicine, Babol University of Medical Sciences, Babol, Iran.
Shiva MohammadiPediatric Cell and Gene Therapy Research Centre, Gene, Cell & Tissue Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
Parsa LorestaniStudents Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Amir Ali HamidiehPediatric Cell and Gene Therapy Research Centre, Gene, Cell & Tissue Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
Mohammad Amin HabibiClinical Research Development Center, Qom University of Medical Sciences, Qom, Iran.
Farhad Jadidi-NiaraghImmunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Funding

Tabriz University of Medical Sciences, Tabriz, Iran 66392, 66207
6 · The paper itself

Abstract

backgroundDespite ongoing advances and introducing innovative therapeutic approaches for the treatment of multiple myeloma (MM), relapses are common, with low overall survival rates. G protein-coupled receptor, class C, group 5, and member D (GPRC5D) has been expressed in several myeloma cell lines and has demonstrated encouraging outcomes results in

objectiveWe aimed to investigate the safety and efficacy of GPRC5D-targeted CAR T cell therapies in MM patients.

methodsOn August 24, 2023, the databases of PubMed, Scopus, Embase, and Web of Science were systematically searched for pertinent studies. After completing a two-step title/abstract and full-text screening process, the eligible studies were included.

resultsFollowing the screening of 107 articles, four studies of 130 multiple myeloma patients treated with GPRC5D-targeted CAR T-cell therapy were included. The meta-analyses showed an ORR of 87% (95% CI [81- 93%]), with 74% (95% CI [65-73%]) for those with prior BCMA-targeted therapy and 88% (95% CI [78-99%]) for those without. PR was 25%, VGPR 33%, and CR/sCR 48%, with 65% achieving MRD-negativity. In terms of safety, hematologic AEs were common, with anemia reported in 86% of patients. Non-hematologic common AEs included CRS (83%, 5% grade ≥3) and hypocalcemia (63%, 10% grade ≥3). No significant publication bias was detected.

conclusionGPRC5D is an active and safe target that shows promising results in the treatment of relapsed and/or refractory (R/R) MM and heavily pretreated patients.

Indexed as

Antineoplastic AgentsImmunotherapy, AdoptiveMultiple MyelomaReceptors, Chimeric AntigenReceptors, G-Protein-CoupledHumansAntineoplastic AgentsReceptors, Chimeric AntigenReceptors, G-Protein-CoupledCAR T Cellchimeric antigen receptorGPRC5Dhematologic AEs.immunotherapyMultiple myeloma

Identifiers

PMID39901537

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.